Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2143-2158
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2143
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2143
Ref. | Inclusion criteria | Number of RCTs (total number of patients) | Endpoint parameters (primary endpoint listed on first line of each entry) | RR, HR or OR for primary endpoint | 95%CI | Comments |
Imperiale et al[102], 1990 | RCTs of patients with acute AH receiving corticosteroids vs placebo | 11 (562) | Mortality Hepatic encephalopathy | RR = 0.63 | 0.5-0.8 | Positive study (P = 0.025) |
Christensen et al[101], 1995 | RCTs evaluating short term effect on survival of treatment with glucocorticoids vs placebo for AH | 13 (659) | Mortality Age Serum bilirubin Ascites Male gender Hepatic encephalopathy | RR = 0.78 | 0.51-1.18 | Negative study (P = 0.2) |
Mathurin et al[55], 2002 | RCTs during 1984-1992 of patients receiving glucocorticoids vs placebo | 3 (215) | Survival Age Liver function tests DF Hepatic encephalopathy Gender Serum creatinine Ascites Leukocyte count | OR = 0.39 | 0.22-0.71 | Positive study (P = 0.002) Used individual patient data analysis to increase statistical rigor for the meta-analysis |
Rambaldi et al[100], 2008 | RCTs of patients with severe, clinically overt AH diagnosed by clinical and biochemical criteria, treated with glucocorticoids vs placebo (or no intervention) | 15 (721) | Mortality Liver-related mortality Symptoms and complications Liver function tests Liver histology Adverse events | RR = 0.83 | 0.63-1.11 | Negative study (P = 0.21) |
Mathurin et al[99], 2011 | RCTs from 1984 to 2006 with specific data on DF ≥ 32 or hepatic encephalopathy, of corticosteroids vs placebo, enteral nutrition or antioxidants | 5 (418) | Survival DF Lille score Liver function tests | Complete responder: HR = 0.18 | Complete responder: 0.05-0.71 | Positive study Complete responders (P = 0.005) |
Serum creatinine Ascites | Partial responder: HR = 0.38 | Partial responder: 0.17-0.87 | Partial responders (P = 0.03) | |||
Hepatic encephalopathy Age | Null responder: HR = 0.81 | Null responder: 0.45-1.45 | Null responders (P = 0.46) | |||
Gender Leukocyte count | Used individual patient data analysis to increase statistical rigor for the meta-analysis |
- Citation: Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2143-2158
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2143.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2143